Skip to main content
Fig. 1 | Journal of Ovarian Research

Fig. 1

From: Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

Fig. 1

S109 inhibits ovarian cancer growth and RanBP1 nuclear export. a Structure of S109. b Suppression of the cell of growth of ovarian cancer cells by S109. The growth of SKOV-3 cells were cultured with indicated doses of S109 for 72 h and analyzed by the CCK-8 assay. All data are presented as the mean ± SEM of three replicates (*P < 0.05). c S109 reduces expression level of CRM1 protein. SKOV-3 cells were treated with indicated doses of S109 for 12 h, and the whole cell lysates were analyzed by immunoblotting. d S109 reduces expression level of CRM1 protein in OVCAR cells. Cells were treated with indicated doses of S109 for 12 h, and the whole cell lysates were analyzed by immunoblotting. e S109 inhibits nuclear export of RanBP1. Cells were treated with indicated doses of S109 for 2 h. Fixed cells were stained for RanBP1 and DAPI and analyzed by fluorescence microscopy

Back to article page